Bavarian Nordic (OTCMKTS:BVNRY) Releases Quarterly Earnings Results

Key Points

• Bavarian Nordic reported quarterly earnings of $0.23 per share, with a net margin of 21.11% and a return on equity of 11.89%.
• The company's market capitalization stands at $2.91 billion and its price-to-earnings ratio is 15.38.
• Bavarian Nordic specializes in developing life-saving vaccines, including those for smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) released its earnings results on Friday. The company reported $0.23 earnings per share for the quarter, Zacks reports. Bavarian Nordic had a net margin of 21.95% and a return on equity of 12.75%. The business had revenue of $251.14 million for the quarter.

Bavarian Nordic Price Performance

Shares of OTCMKTS:BVNRY traded down $0.16 during trading on Wednesday, reaching $12.21. 1,022 shares of the company's stock traded hands, compared to its average volume of 7,779. Bavarian Nordic has a 12 month low of $6.60 and a 12 month high of $13.51. The stock has a market capitalization of $2.89 billion, a P/E ratio of 14.03 and a beta of 1.36. The company has a 50 day moving average of $10.63 and a 200-day moving average of $8.93.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.